Current stock page

Stock Analysis

BeOne Medicines AG (ONC) Stock Analysis

BeOne Medicines AG (ONC) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

ONC Stock Analysis Summary

BeOne Medicines AG (ONC) currently has an AIQ Score of 80/100, indicating a very bullish setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 71/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

ONC at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$416.54
AIQ Score80/100
Overall ViewVery Bullish
Technical Analysis ConsensusStrong Buy
Market Cap$47.36B
P/E Ratio (TTM)66.97
Forward P/E—
EPS (Q3 FY2026)$3.38
Revenue (Q3 FY2026)$1.89B
Dividend Yield (TTM)0.00%
Beta0.68
Volume345.46K
52-week range$253.95-$424.73
RSI 1467.46
50-Day SMA$369.18
200-Day SMA$327.80
Analyst Price Target$437.80
Next EarningsFeb 25, 2027
As of Nov 13, 2026 · Market close

ONCBeOne Medicines AG

Healthcare / Biotechnology

Leader

Sector Leader

Very BullishEdge 10/10
$416.54+$0.58 (+0.14%)

Latest quote

  • Momentum
    91
  • Value
    71
  • Quality
    78
  • Risk resilience
    72
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

ONC Stock Analysis Summary

BeOne Medicines AG (ONC) currently has an AIQ Score of 80/100, indicating a very bullish setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 71/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Very Bullish

In a very bullish regime, ONC has AIQ Score of 80/100 with Momentum base of 91/100 and fading Value at 71/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (91/100) leads while Value (71/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 0.14% stock move · ONC classified in Biotechnology.

Current Evidence

Very BullishONC is in a very bullish AIQ regime; Momentum is the strongest visible factor at 91/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is ONC Bullish or Bearish Right Now?

ONC currently has a very bullish overall setup. Momentum is the strongest factor at 91/100, while Value is weakest at 71/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 78/100.
  • - Momentum is constructive at 91/100.
  • - Risk Resilience is supportive at 72/100.
  • - Price is +12.83% above its 50-day SMA.
  • - Analyst target implies +5.10% upside from the latest quote.
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

ONC's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 3 neutral, and 7 sell votes. ONC's 14-day RSI is 67.46, which places the stock in a constructive momentum range. ONC's beta is 0.68, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in ONC?

The largest recent change in ONC is Momentum moving up by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+6.0
Quality
+0.0
Risk
+1.0

What Would Change the ONC Outlook?

The current very bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

ONC Decision Framework

Public evidence layers, setup checks, and risk context for BeOne Medicines AG.

BeOne Medicines AG (ONC) Stock Analysis

BeOne Medicines AG has an AIQ Score of 80/100 in a Very Bullish regime. Momentum is strongest at 91/100. Beta is 0.68, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextONC is in a Very Bullish AIQ regime with score 80/100.
Signal ConflictThe primary conflict is that momentum leads at 91/100 while value lags at 71/100.
Factor EvidenceMomentum 91/100 · Value 71/100 · Quality 78/100 · Risk 72/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 91/100.

TimingPass

Momentum is 91/100 and RSI (14) is 67.5.

Regime fitPass

ONC is in a Very Bullish regime at 80/100.

Risk controlPass

Risk factor is 72/100 with beta 0.68 and annual volatility 34.16%.

ConflictWait

Current conflict: momentum leads at 91/100 while value lags at 71/100.

AIQ Score
80/100
Price
$416.54
Beta
0.68
RSI (14)
67.5

ONC Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

ONC Fundamentals

ONC valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$1.89B
Net income
$384.71M
Free cash flow
$473.53M
View full ONC fundamental analysis

ONC Technical Analysis

ONC technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
67.46
Price vs SMA-50
+12.83%
View full ONC technical analysis

ONC Stock Catalysts

Track ONC earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 25, 2027
Analyst target
$437.80
News items
0
View ONC earnings and stock catalysts

ONC Dividend Analysis

ONC dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View ONC dividend history and analysis

ONC Financial Data

ONC revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$1.89B
EPS
$3.38
Periods
8
View ONC financials

ONC Risk Analysis

ONC volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.68
Risk score
72/100
1Y volatility
34.16%
View ONC risk analysis

ONC Stock News

ONC stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read ONC stock news

ONC vs Biotechnology Peers

Current peer cohort: ONC · ORKA · PCVX · PGEN · PRAX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
ONC
Current stock
80/10071/10091/10072/1000.4234.16%Current
ORKA
Oruka Therapeutics, Inc.
77/100—81/10053/1002.2969.09%ONC vs ORKA
PCVX
Vaxcyte, Inc.
66/100—81/10053/1000.7956.19%ONC vs PCVX
PGEN
Precigen, Inc.
55/10063/10055/10031/1000.5785.43%ONC vs PGEN
PRAX
Praxis Precision Medicines, Inc.
57/100—48/10047/1001.1375.11%ONC vs PRAX
Pairwise Compare links: ORKA · PCVX · PGEN · PRAXONC vs ORKAONC vs PCVXONC vs PGENONC vs PRAXCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a ONC stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for ONC: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
66.97
As of Nov 13, 2026
Revenue growth
33.81%
Gross margin
88.39%
Current debt / equity
0.2
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$1.89B
Quarter net income
$384.71M
Quarter free cash flow
$473.53M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
67.46
MACD
14.24

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
72/100
Beta
0.68
Annual volatility
34.16%
Max drawdown
-30.89%

ONC Stock FAQ

What is ONC stock price today?

BeOne Medicines AG's current stock price is $416.54. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is ONC bullish or bearish right now?

ONC's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is ONC's market cap?

ONC's market cap is $47.36B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is ONC's current P/E ratio?

ONC's current P/E ratio is 66.97 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is ONC's RSI?

ONC's 14-day RSI is 67.46 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is ONC above its 50-day and 200-day moving averages?

ONC is 12.83% from its 50-day SMA and 27.07% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is ONC's next earnings date?

ONC's next earnings date is currently listed as Feb 25, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does ONC pay a dividend?

ONC's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.